Abstract
Background: Inappropriate renal phosphate transport may alter serum phosphate concentration and bone mineralization, and it may also increase the risk of renal lithiasis or soft-tissue calcifications. Molecular identification of renal phosphate transporters and regulatory proteins has improved our knowledge of the mechanisms that control phosphate balance. This summary reviews recent findings regarding the consequences of mutations affecting several human genes encoding for phosphate transporters or regulatory proteins. Further, it describes the role played by the fibroblast growth factor 23–Klotho axis in phosphate homeostasis and its involvement in the pathophysiology of phosphate disturbances in chronic kidney diseases. Conclusions: This progress may allow development of new drugs that interfere with phosphate transporters, hormonal receptors or associated proteins to improve treatment and to help prevent secondary hyperparathyroidism.
Journal Section:
Pediatric Hot Topics
References
1.
Prié D, Beck L, Urena P, Friedlander G: Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens 2005;14:318–324.
[PubMed]
2.
Prié D, Beck L, Friedlander G, Silve C: Sodium-phosphate cotransporters, nephrolithiasis and bone demineralization. Curr Opin Nephrol Hypertens 2004;13:675–681.
3.
Murer H, Hernando N, Forster I, Biber J: Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 2000;80:1373–1409.
[PubMed]
4.
Ohkido I, Segawa H, Yanagida R, Nakamura M, Miyamoto K: Cloning, gene structure and dietary regulation of the type-IIc Na/Pi cotransporter in the mouse kidney. Pflügers Arch 2003;446:106–115.
[PubMed]
5.
Prié D, Huart V, Bakouh N, Planelles G, Dellis O, Gérard B, Hulin P, Benqué-Blanchet F, Silve C, Grandchamp B, Friedlander G: Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 2002;347:983–991.
[PubMed]
6.
Jüppner H: Novel regulators of phosphate homeostasis and bone metabolism. Ther Apher Dial 2007;11(suppl 1):S3–S22.
7.
Tenenhouse HS, Martel J, Gauthier C, Segawa H, Miyamoto K: Differential effects of Npt2a gene ablation and X-linked Hyp mutation on renal expression of Npt2c. Am J Physiol Renal Physiol 2003;285:F1271–1278.
[PubMed]
8.
Corut A, Senyigit A, Ugur SA, Altin S, Ozcelik U, Calisir H, Yildirim Z, Gocmen A, Tolun A: Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am J Hum Genet 2006;79:650–656.
[PubMed]
9.
Giachelli CM: Vascular calcification mechanisms. J Am Soc Nephrol 2004;15:2959–2964.
[PubMed]
10.
Shenolikar S, Voltz JW, Minkoff CM, Wade JB, Weinman EJ: Targeted disruption of the mouse NHERF-1 gene promotes internalization of proximal tubule sodium-phosphate cotransporter type IIa and renal phosphate wasting. Proc Natl Acad Sci USA 2002;99:11470–11475.
[PubMed]
11.
Karim Z, Gérard B, Bakouh N, Alili R, Leroy C, Beck L, Silve C, Planelles G, Urena-Torres P, Grandchamp B, Friedlander G, Prié D: NHERF1 mutations and responsiveness of renal parathyroid hormone. N Engl J Med 2008;359:1128–1135.
[PubMed]
12.
Mirams M, Robinson BG, Mason RS, Nelson AE: Bone as a source of FGF23: regulation by phosphate? Bone 2004;35:1192–1199.
[PubMed]
13.
Prié D, Ureña Torres P, Friedlander G: Latest findings in phosphate homeostasis. Kidney Int 2009;75:882–889.
14.
Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007;117:4003–4008.
[PubMed]
15.
Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45–51.
[PubMed]
16.
Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006;444:770–774.
[PubMed]
17.
Urena Torres P, Friedlander G, de Vernejoul MC, Silve C, Prié D: Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int 2008;73:102–107.
[PubMed]
18.
Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584–592.
[PubMed]
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.
